RESUMEN
First discovered as an oncogene in leukaemia, recent reports highlight an emerging role for the protooncogene BCL3 in solid tumours. Importantly, BCL3 expression is upregulated in >30% of colorectal cancer cases and is reported to be associated with a poor prognosis. However, the mechanism by which BCL3 regulates tumorigenesis in the large intestine is yet to be fully elucidated. In the present study, it was shown for the first time that knocking down BCL3 expression suppressed cyclooxygenase2 (COX2)/prostaglandin E2 (PGE2) signalling in colorectal cancer cells, a pathway known to drive several of the hallmarks of cancer. RNAimediated suppression of BCL3 expression decreased COX2 expression in colorectal cancer cells both at the mRNA and protein level. This reduction in COX2 expression resulted in a significant and functional reduction (3050%) in the quantity of protumorigenic PGE2 produced by the cancer cells, as shown by enzyme linked immunoassays and medium exchange experiments. In addition, inhibition of BCL3 expression also significantly suppressed cytokineinduced (TNFα or IL1ß) COX2 expression. Taken together, the results of the present study identified a novel role for BCL3 in colorectal cancer and suggested that expression of BCL3 may be a key determinant in the COX2meditated response to inflammatory cytokines in colorectal tumour cells. These results suggest that targeting BCL3 to suppress PGE2 synthesis may represent an alternative or complementary approach to using nonsteroidal antiinflammatory drugs [(NSAIDs), which inhibit cyclooxygenase activity and suppress the conversion of arachidonic acid to prostaglandin], for prevention and/or recurrence in PGE2driven tumorigenesis.